Recently, the depletion of ARID1B has also been proved to increase radiosensitivity in an ARID1A mutant CRC cell line, providing a new perspective for targeting ARID1B in combination with radiotherapy to enhance outcomes of patients with ARID1A-mutant CRC patients [51]. This evidence concerns the gene ARID1B and colorectal carcinoma.